BioCentury
ARTICLE | Clinical News

CTAP101: Phase III started

October 1, 2012 7:00 AM UTC

Cytochroma began the first of 2 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 30 and 60 µg oral CTAP101 once daily for 6 months in about 210 patients. The company has ...